Pfizer Targets Another $1.5B in Cost Cuts By End of 2027 5/23/2024

Tango Stops Early Cancer Trial Over Liver Toxicity, Drops Out of Race Against Roche 5/23/2024

Orna Buys Competing RNA Biotech ReNAgade After Series A Financing 5/23/2024

FDA Flags Hypoglycemia Risk for Novo’s Once-Weekly Insulin Ahead of Adcomm 5/23/2024

Appeals Court Sides With Drugmakers in 340B Case, Allows Limits on Discounts Under Program 5/23/2024

Moderna Among Companies Partnering With OpenAI to Boost AI Efforts 5/23/2024

BioSpace x DIA: Navigating the Emergence of CGT Combination Products 5/23/2024

Do You Need to Love Your Job to Be Happy at Your Job? 5/23/2024

Scientists have used breast cancer cells' weakness against themselves by linking a tumour-selective antibody with a cell-killing drug to destroy hard-to-treat tumours.

The research, published today in Clinical Cancer Research by a team from King's College London and funded by Breast Cancer Now, marks a new method in cancer treatment.

Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth beyond 2030, the Company will continue investing in transformative new technologies and platforms that will shape the future of medicine.

AstraZeneca Sets $80B Revenue Target, Goal of 20 New Drugs by 2030 5/21/2024

FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea 5/21/2024

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology 5/21/2024

Sanofi, Regeneron Post Strong Phase III COPD Data for Dupixent as FDA Decision Looms 5/21/2024

GSK’s Long-Acting Asthma Drug Hits Primary Endpoint in Phase III Trials 5/21/2024

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate 5/21/2024

BIO Axes 30 Staff in Realignment as Congress Advances BIOSECURE Act 5/21/2024

A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic thrombocytopenic purpura (iTTP), a rare disorder characterized by uncontrolled clotting throughout the small blood vessels. The group describes the first clinical use of the drug for iTTP in the New England Journal of Medicine.

HIV has proven a hard target for vaccine design. The most promising approach, germline-targeting (GT), proposes a series of immunizations: a first shot to activate inexperienced B cells - antibody-producing white blood cells - followed by a sequence of immunogens that are more and more like the HIV Envelope (Env) protein. The ultimate goal of GT immunization is to coach B cells into producing broadly neutralizing antibodies (bnAbs) capable of binding to conserved sites on HIV Env, which seldom change despite HIV's penchant for rapid diversification.

Amgen Wins FDA Approval for Difficult-to-Treat Lung Cancer 5/17/2024